OBJECTIVE To establish anticoagulation pharmaceutical service model based on the integrated theory of health behavior change （ITHBC）， and analyze its effects. METHODS Referring to relevant literature and soliciting opinions from 8 experts from departments such as pharmacy， respiratory medicine， and vascular surgery， a anticoagulation pharmaceutical service model based on ITHBC was ultimately formed. VTE inpatients were selected from The First Affiliated Hospital of Shihezi University from December 2023 to June 2024 as the research subjects. They were randomly assigned into intervention group （58 cases） and control group （60 cases） using a random number table method. The intervention group implemented pharmacist-led anticoagulant pharmaceutical service model based on ITHBC， while the control group adopted a conventional anticoagulant pharmaceutical service model. The anticoagulation-related outcomes of two groups were compared after 3 months： anticoagulation compliance rate， the incidence of adverse drug reactions， the score of medication adherence and compliance rate of anticoagulant prescription； economic evaluation was conducted. RESULTS After implementing ITHBC-based anticoagulant pharmaceutical services for 3 months， the intervention group had higher anticoagulation compliance rate， score of medication adherence， and compliance rate of anticoagulant prescription than the control group （P＜0.05）. There was no statistically significant difference in the total incidence of adverse drug reactions between the two groups （P＞0.05）. For every 1% point increase in anticoagulant compliance rate， the hospital needed to invest 4.35 yuan additionally in anticoagulant pharmaceutical service fees. Compared with China’s per capita gross domestic product （GDP， 89 358 yuan） in 2023， the incremental cost-effectiveness ratio value that increased the anticoagulation compliance rate by 50% is far less than one time of per capita GDP. CONCLUSIONS The pharmacist- led anticoagulant pharmaceutical service model based on ITHBC can effectively improve the outcomes of anticoagulant therapy for VTE patients， enhance medication compliance， improve patients’ awareness and recognition of adverse drug reactions to anticoagulants， and has certain economic and social benefits.

Objective To investigate the feasibility of combined laparoscopic resection of gallbladder and other viscera. Methods The clinical data of 69 cases of combined laparoscopic resection of gallbladder and other viscera from January 1999 to July 2004 were reviewed retrospectively. Results The laparoscopic operation was successful in 69cases,and no case was converted to laparotomy.The average operation time was(85.5?18.6)min,and the time of return of gastrointestinal function was(27.3?6.2)h. The average hospitalization time after operation was(3.9?0.8)d.There were no operative or postoperative complications , and the therapeutic results were satisfactory. Conclusions The combined laparoscopic resection of the gall bladder and other viscera is safe and feasible. It is possible to treat gallbladder diseases and associated lesions of abdominal viscera simultaneously. The lesions of several organs can be treated at one operation. This can significantly decrease patients′ pain and lower the cost of treatment, and is worthy of wide usage.